The estimated Net Worth of Linda A Fitzpatrick is at least $946 Thousand dollars as of 5 March 2024. Ms Fitzpatrick owns over 8,750 units of Sutro Biopharma Inc stock worth over $350,637 and over the last 6 years she sold STRO stock worth over $0. In addition, she makes $595,789 as Chief People & Communications Officer at Sutro Biopharma Inc.
Ms has made over 15 trades of the Sutro Biopharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 8,750 units of STRO stock worth $40,338 on 5 March 2024.
The largest trade she's ever made was exercising 17,875 units of Sutro Biopharma Inc stock on 3 March 2023 worth over $82,404. On average, Ms trades about 5,640 units every 83 days since 2018. As of 5 March 2024 she still owns at least 76,060 units of Sutro Biopharma Inc stock.
You can see the complete history of Ms Fitzpatrick stock trades at the bottom of the page.
Linda A. Fitzpatrick is the Chief People & Communications Officer at Sutro Biopharma Inc.
As the Chief People & Communications Officer of Sutro Biopharma Inc, the total compensation of Ms Fitzpatrick at Sutro Biopharma Inc is $595,789. There are 7 executives at Sutro Biopharma Inc getting paid more, with William Newell having the highest compensation of $3,817,120.
Ms Fitzpatrick is 64, she's been the Chief People & Communications Officer of Sutro Biopharma Inc since . There are 5 older and 15 younger executives at Sutro Biopharma Inc. The oldest executive at Sutro Biopharma Inc is Dr. Shabbir T. Anik, 68, who is the Chief Technical Operations Officer.
Linda's mailing address filed with the SEC is C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080.
Over the last 6 years, insiders at Sutro Biopharma Inc have traded over $14,451,171 worth of Sutro Biopharma Inc stock and bought 750,858 units worth $10,652,478 . The most active insiders traders include Corp /De/ Celgene, John Gordon Freund, and Daniel Janney. On average, Sutro Biopharma Inc executives and independent directors trade stock every 19 days with the average trade being worth of $129,762. The most recent stock trade was executed by Jane Chung on 9 August 2024, trading 18,750 units of STRO stock currently worth $86,438.
at sutro biopharma we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. our focus is aimed primarily on next generation cancer therapeutics — antibody conjugates and bispecific antibodies. unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell. our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency. our approach to discovery, without the cell, is also transcending the the limitations of biologics manufacturing. sutro has the world’s only cgmp cell-free manufacturing facility located in san carlos, california. this state-of- the-art facility confers an important competitive advantage as we head into human clinical trials in 2018. in addition to developing our own oncology pipeline, sutro biopharma is coll
Sutro Biopharma Inc executives and other stock owners filed with the SEC include: